Glofitamab Plus Gemcitabine and Oxaliplatin vs Rituximab Plus GemOx in Patients With Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Outcomes From the 3-Year Follow-Up of STARGLO

  • Abramson, Jeremy S.; 
  • Ku, Matthew; 
  • Fox, Christopher P.; 
  • Huang, Hui-Qiang; 
  • Zhang, Huilai; 
  • ... Kim, Won-Seog; 
  • 외 14명
Citations

WEB OF SCIENCE

0

키워드

ABCL; aggressive B-cell lymphoma; diffuse large B-cell lymphoma; relapsed/refractory; transplant-ineligible; bispecific antibodies; phase 3
제목
Glofitamab Plus Gemcitabine and Oxaliplatin vs Rituximab Plus GemOx in Patients With Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Outcomes From the 3-Year Follow-Up of STARGLO
저자
Abramson, Jeremy S.; Ku, Matthew; Fox, Christopher P.; Huang, Hui-Qiang; Zhang, Huilai; Townsend, William; Yoon, Dok Hyun; Kim, Won-Seog; Abdulhaq, Haifaa; Herbaux, Charles; Zaucha, Jan M.; Chang, Hung; Mulvihill, Estefania; Kesavan, Murali; Kallemeijn, Martine; Ta, Richard; Choeurng, Voleak; Bottos, Alessia; Lundberg, Linda; Gregory, Gareth P.
발행일
2026-08
유형
Meeting Abstract
저널명
Clinical Lymphoma, Myeloma and Leukemia
권
26
페이지
S905 ~ S906